Skip to the stories
Sunday, 22 November 2026
Saved

Next edition

5:28

Medical Science

Oral PCSK9 inhibitors reduce bad cholesterol by fifty-eight percent in review

A systematic review of five randomised controlled trials found that oral PCSK9 inhibitors reduce low-density lipoprotein cholesterol by an average of 58.37 percent compared with a placebo.

FTMQ Health, written by our newsroom0 views

Share

Oral proprotein convertase subtilisin/kexin type 9 inhibitors reduce low-density lipoprotein cholesterol by an average of 58.37 percent compared with placebo in adults with hypercholesterolaemia, Bioengineer.org reported. The findings come from a systematic review and meta-analysis of five randomised controlled trials in humans. SciTechDaily separately reported on clinical trial results showing a once-daily pill slashed bad cholesterol by nearly 65 percent. [1][2][7]

Bioengineer.org reported that the investigators synthesized both early-phase dose-finding investigations and clinical trials to evaluate the drugs. The investigational oral therapies achieved substantial and statistically significant lipid-lowering efficacy. Furthermore, Wisevoter reported that the United States Food and Drug Administration has approved Lipfendra, which is the first oral PCSK9 cholesterol pill. [1][4][7]

The systematic review established that the oral therapies maintained an overall safety profile comparable to inactive placebos, according to Bioengineer.org. Clinical trials are biomedical research studies conducted on human participants that generate data on safety, efficacy, and proper dosage. [1][7]

PCSK9 is an enzyme encoded by the PCSK9 gene on human chromosome 1, and it is the ninth member of the proprotein convertase family of proteins. The PCSK9 gene contains one of 27 loci associated with an increased risk of coronary artery disease. [5]

Share

In short

  • A systematic review of five randomised controlled trials found oral PCSK9 inhibitors reduced LDL cholesterol by an average of 58.37 percent.
  • The oral therapies maintained an overall safety profile comparable to inactive placebos in adults with hypercholesterolaemia.
  • The Food and Drug Administration approved Lipfendra as the first oral PCSK9 cholesterol pill.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Oral PCSK9 Inhibitors Cut LDL Cholesterol by Fifty-Eight Percent in Clinical TrialsBioengineer.org, 17h ago (the report this story comes from)
  2. [2]New Once-Daily Pill Slashes Bad Cholesterol by Nearly 65% in Clinical TrialSciTechDaily, 1d ago
  3. [3]Lancet Meta-Analysis of 115 Clinical Trials Compares Long-Term Antidepressant Maintenance OutcomesCASRAI, 1d ago
  4. [4]FDA Approves Lipfendra, First Oral PCSK9 Cholesterol PillWisevoter, 1d ago

Background

  1. [5]PCSK9 on Wikipedia
  2. [6]1975 in Japanese music on Wikipedia
  3. [7]Clinical trial on Wikipedia
  4. [8]RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials FTMQ Health, 6d ago
  5. [9]International trial tests oral bacterial lysate to prevent infant wheeze FTMQ Health, 9d ago

Our newsroom writes these reports with the help of software, from the 9 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Medical Science

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.